These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32084592)

  • 21. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes.
    Wolgast LR; Arslan AA; Wu XX; Beyda JN; Pengo V; Rand JH
    J Thromb Haemost; 2017 Jul; 15(7):1412-1421. PubMed ID: 28393472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?
    Berkun Y; Simchen MJ; Strauss T; Menashcu S; Padeh S; Kenet G
    Lupus; 2014 Sep; 23(10):986-93. PubMed ID: 24729280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL].
    Mekinian A; Vicaut E; Cohen J; Bornes M; Kayem G; Fain O
    Gynecol Obstet Fertil Senol; 2018; 46(7-8):598-604. PubMed ID: 30041771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
    Devaux CA; Camoin-Jau L; Mege JL; Raoult D
    J Microbiol Immunol Infect; 2021 Feb; 54(1):37-45. PubMed ID: 33500211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
    Khizroeva J; Bitsadze V; Tincani A; Makatsariya A; Arslanbekova M; Babaeva N; Tsibizova V; Shkoda A; Makatsariya N; Tretyakova M; Solopova A; Gadaeva Z; Vorobev A; Khamani I; Aslanova Z; Nakaidze I; Mischenko A; Grigoreva K; Kunesko N; Egorova E; Mashkova T
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6157-6164. PubMed ID: 34044735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).
    Cuadrado MJ; Bertolaccini ML; Seed PT; Tektonidou MG; Aguirre A; Mico L; Gordon C; Ruiz-Irastorza G; Egurbide MV; Gil A; Espinosa G; Houssiau F; Rahman A; Martin H; McHugh N; Galindo M; Akil M; Amigo MC; Murru V; Khamashta MA
    Rheumatology (Oxford); 2014 Feb; 53(2):275-84. PubMed ID: 24097288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EULAR recommendations for the management of antiphospholipid syndrome in adults.
    Tektonidou MG; Andreoli L; Limper M; Amoura Z; Cervera R; Costedoat-Chalumeau N; Cuadrado MJ; Dörner T; Ferrer-Oliveras R; Hambly K; Khamashta MA; King J; Marchiori F; Meroni PL; Mosca M; Pengo V; Raio L; Ruiz-Irastorza G; Shoenfeld Y; Stojanovich L; Svenungsson E; Wahl D; Tincani A; Ward MM
    Ann Rheum Dis; 2019 Oct; 78(10):1296-1304. PubMed ID: 31092409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
    Miranda S; Billoir P; Damian L; Thiebaut PA; Schapman D; Le Besnerais M; Jouen F; Galas L; Levesque H; Le Cam-Duchez V; Joannides R; Richard V; Benhamou Y
    PLoS One; 2019; 14(3):e0212614. PubMed ID: 30870459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers.
    Tonello M; Mattia E; Favaro M; Del Ross T; Calligaro A; Salvan E; Hoxha A; Fedrigo M; Ruffatti A
    Thromb Res; 2019 May; 177():157-160. PubMed ID: 30903876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
    Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
    Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of the antiphospholipid syndrome in adults].
    Doms J; Horisberger A; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):670-674. PubMed ID: 32270932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
    Ames PR; Margaglione M; Ciampa A; Colaizzo D; Ferrara F; Iannaccone L; Vincenzobrancaccio
    Thromb Res; 2011 Jun; 127(6):595-9. PubMed ID: 21371740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
    Signorelli F; Balbi GGM; Aikawa NE; Silva CA; Kupa LVK; Medeiros-Ribeiro AC; Yuki EF; Pasoto SG; Saad CG; Borba EF; Seguro LPC; Pedrosa T; Oliveira VAA; Costa ALCS; Ribeiro CT; Santos REB; Andrade DCO; Bonfá E
    Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.
    Les I; Parraza N; Anaut P; Eguiluz S; Sánchez C; Preciado ME; Loza JÁ; Andía A
    Rheumatol Int; 2018 Feb; 38(2):229-238. PubMed ID: 29124399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary prevention in antiphospholipid antibody carriers.
    Bertero MT
    Lupus; 2012 Jun; 21(7):751-4. PubMed ID: 22635222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.
    Fredi M; Andreoli L; Aggogeri E; Bettiga E; Lazzaroni MG; Le Guern V; Lojacono A; Morel N; Piette JC; Zatti S; Costedoat-Chalumeau N; Tincani A
    Front Immunol; 2018; 9():864. PubMed ID: 29867924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.
    Ruiz-Irastorza G; Hunt BJ; Khamashta MA
    Arthritis Rheum; 2007 Dec; 57(8):1487-95. PubMed ID: 18050167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombotic risk in the antiphospholipid syndrome.
    Lim W
    Semin Thromb Hemost; 2014 Oct; 40(7):741-6. PubMed ID: 25299926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity.
    Pyo JY; Jung SM; Lee SW; Song JJ; Lee SK; Park YB
    Yonsei Med J; 2017 Nov; 58(6):1128-1134. PubMed ID: 29047236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome.
    Mattia E; Ruffatti A; Tonello M; Meneghel L; Robecchi B; Pittoni M; Gallo N; Salvan E; Teghil V; Punzi L; Plebani M
    Clin Chem Lab Med; 2014 Sep; 52(9):1329-33. PubMed ID: 24651022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.